| Reynaldo Lluberes Martinez, | |
|
Urb Villa Fontana, Via Diana Tr3, Carolina, PR 00983 | |
| (787) 340-5934 | |
| Not Available |
| Full Name | Reynaldo Lluberes Martinez |
|---|---|
| Gender | Male |
| Speciality | Nurse Anesthetist, Certified Registered |
| Location | Urb Villa Fontana, Carolina, Puerto Rico |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063149805 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 120795 (Florida) | Primary |
| Entity Name | Ocala Endoscopy Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386693240 PECOS PAC ID: 6305745936 Enrollment ID: O20040102000627 |
News Archive
When 225 researchers from around the world convened in Miami to exchange the latest on β amyloid positron emission tomography in January, there was a palpable sense of urgency. At the 6th Annual Human Amyloid Imaging (HAI) Conference, the possibility of approval, potentially within months, of the first amyloid-scanning compound for clinical use hung over the room.
University Hospitals Case Medical Center is one of 12 sites conducting the first Phase 2 clinical trial of a gene therapy for Alzheimer's disease (AD). The study uses a viral-based gene transfer system called CERE-110, which is designed to deliver nerve growth factor (NGF) into the brain.
Epilepsy remains one of the most common neurological conditions, affecting one in 26 Americans in their lifetime, with one-third having a form of the condition that resists treatment or effective management. With those statistics in mind, more than 5,200 neurologists, scientists, nurses and health professionals came to Philadelphia December 4-8 for the 2015 American Epilepsy Society Annual Meeting to discuss new discoveries and emerging technologies that can lead to more effective treatment.
Cardium Therapeutics announced that it has gained exclusive access to commercial development rights for certain novel supramacromolecular polymer complexes enabling regulatable and localized topical delivery of nitric oxide for prolonged periods of one to three weeks, to broaden and expand the Company's wound healing and tissue regeneration portfolio.
› Verified 8 days ago
| Entity Name | Us Anesthesia Partners Of Florida Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518910520 PECOS PAC ID: 0345143152 Enrollment ID: O20040129000594 |
News Archive
When 225 researchers from around the world convened in Miami to exchange the latest on β amyloid positron emission tomography in January, there was a palpable sense of urgency. At the 6th Annual Human Amyloid Imaging (HAI) Conference, the possibility of approval, potentially within months, of the first amyloid-scanning compound for clinical use hung over the room.
University Hospitals Case Medical Center is one of 12 sites conducting the first Phase 2 clinical trial of a gene therapy for Alzheimer's disease (AD). The study uses a viral-based gene transfer system called CERE-110, which is designed to deliver nerve growth factor (NGF) into the brain.
Epilepsy remains one of the most common neurological conditions, affecting one in 26 Americans in their lifetime, with one-third having a form of the condition that resists treatment or effective management. With those statistics in mind, more than 5,200 neurologists, scientists, nurses and health professionals came to Philadelphia December 4-8 for the 2015 American Epilepsy Society Annual Meeting to discuss new discoveries and emerging technologies that can lead to more effective treatment.
Cardium Therapeutics announced that it has gained exclusive access to commercial development rights for certain novel supramacromolecular polymer complexes enabling regulatable and localized topical delivery of nitric oxide for prolonged periods of one to three weeks, to broaden and expand the Company's wound healing and tissue regeneration portfolio.
› Verified 8 days ago
| Entity Name | Mnh Gi Anesthesia & Pain Management Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033436613 PECOS PAC ID: 2860689759 Enrollment ID: O20101203000902 |
News Archive
When 225 researchers from around the world convened in Miami to exchange the latest on β amyloid positron emission tomography in January, there was a palpable sense of urgency. At the 6th Annual Human Amyloid Imaging (HAI) Conference, the possibility of approval, potentially within months, of the first amyloid-scanning compound for clinical use hung over the room.
University Hospitals Case Medical Center is one of 12 sites conducting the first Phase 2 clinical trial of a gene therapy for Alzheimer's disease (AD). The study uses a viral-based gene transfer system called CERE-110, which is designed to deliver nerve growth factor (NGF) into the brain.
Epilepsy remains one of the most common neurological conditions, affecting one in 26 Americans in their lifetime, with one-third having a form of the condition that resists treatment or effective management. With those statistics in mind, more than 5,200 neurologists, scientists, nurses and health professionals came to Philadelphia December 4-8 for the 2015 American Epilepsy Society Annual Meeting to discuss new discoveries and emerging technologies that can lead to more effective treatment.
Cardium Therapeutics announced that it has gained exclusive access to commercial development rights for certain novel supramacromolecular polymer complexes enabling regulatable and localized topical delivery of nitric oxide for prolonged periods of one to three weeks, to broaden and expand the Company's wound healing and tissue regeneration portfolio.
› Verified 8 days ago
| Entity Name | Kf Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184031528 PECOS PAC ID: 3779705918 Enrollment ID: O20141104000917 |
News Archive
When 225 researchers from around the world convened in Miami to exchange the latest on β amyloid positron emission tomography in January, there was a palpable sense of urgency. At the 6th Annual Human Amyloid Imaging (HAI) Conference, the possibility of approval, potentially within months, of the first amyloid-scanning compound for clinical use hung over the room.
University Hospitals Case Medical Center is one of 12 sites conducting the first Phase 2 clinical trial of a gene therapy for Alzheimer's disease (AD). The study uses a viral-based gene transfer system called CERE-110, which is designed to deliver nerve growth factor (NGF) into the brain.
Epilepsy remains one of the most common neurological conditions, affecting one in 26 Americans in their lifetime, with one-third having a form of the condition that resists treatment or effective management. With those statistics in mind, more than 5,200 neurologists, scientists, nurses and health professionals came to Philadelphia December 4-8 for the 2015 American Epilepsy Society Annual Meeting to discuss new discoveries and emerging technologies that can lead to more effective treatment.
Cardium Therapeutics announced that it has gained exclusive access to commercial development rights for certain novel supramacromolecular polymer complexes enabling regulatable and localized topical delivery of nitric oxide for prolonged periods of one to three weeks, to broaden and expand the Company's wound healing and tissue regeneration portfolio.
› Verified 8 days ago
| Entity Name | Ccsc Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598161051 PECOS PAC ID: 4486971686 Enrollment ID: O20150327001222 |
News Archive
When 225 researchers from around the world convened in Miami to exchange the latest on β amyloid positron emission tomography in January, there was a palpable sense of urgency. At the 6th Annual Human Amyloid Imaging (HAI) Conference, the possibility of approval, potentially within months, of the first amyloid-scanning compound for clinical use hung over the room.
University Hospitals Case Medical Center is one of 12 sites conducting the first Phase 2 clinical trial of a gene therapy for Alzheimer's disease (AD). The study uses a viral-based gene transfer system called CERE-110, which is designed to deliver nerve growth factor (NGF) into the brain.
Epilepsy remains one of the most common neurological conditions, affecting one in 26 Americans in their lifetime, with one-third having a form of the condition that resists treatment or effective management. With those statistics in mind, more than 5,200 neurologists, scientists, nurses and health professionals came to Philadelphia December 4-8 for the 2015 American Epilepsy Society Annual Meeting to discuss new discoveries and emerging technologies that can lead to more effective treatment.
Cardium Therapeutics announced that it has gained exclusive access to commercial development rights for certain novel supramacromolecular polymer complexes enabling regulatable and localized topical delivery of nitric oxide for prolonged periods of one to three weeks, to broaden and expand the Company's wound healing and tissue regeneration portfolio.
› Verified 8 days ago
| Entity Name | Fpra Anesthesia Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952756728 PECOS PAC ID: 0547554099 Enrollment ID: O20160808000431 |
News Archive
When 225 researchers from around the world convened in Miami to exchange the latest on β amyloid positron emission tomography in January, there was a palpable sense of urgency. At the 6th Annual Human Amyloid Imaging (HAI) Conference, the possibility of approval, potentially within months, of the first amyloid-scanning compound for clinical use hung over the room.
University Hospitals Case Medical Center is one of 12 sites conducting the first Phase 2 clinical trial of a gene therapy for Alzheimer's disease (AD). The study uses a viral-based gene transfer system called CERE-110, which is designed to deliver nerve growth factor (NGF) into the brain.
Epilepsy remains one of the most common neurological conditions, affecting one in 26 Americans in their lifetime, with one-third having a form of the condition that resists treatment or effective management. With those statistics in mind, more than 5,200 neurologists, scientists, nurses and health professionals came to Philadelphia December 4-8 for the 2015 American Epilepsy Society Annual Meeting to discuss new discoveries and emerging technologies that can lead to more effective treatment.
Cardium Therapeutics announced that it has gained exclusive access to commercial development rights for certain novel supramacromolecular polymer complexes enabling regulatable and localized topical delivery of nitric oxide for prolonged periods of one to three weeks, to broaden and expand the Company's wound healing and tissue regeneration portfolio.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Reynaldo Lluberes Martinez, Urb Villa Fontana, Via Diana Tr3, Carolina, PR 00983 Ph: (787) 340-5934 | Reynaldo Lluberes Martinez, Urb Villa Fontana, Via Diana Tr3, Carolina, PR 00983 Ph: (787) 340-5934 |
News Archive
When 225 researchers from around the world convened in Miami to exchange the latest on β amyloid positron emission tomography in January, there was a palpable sense of urgency. At the 6th Annual Human Amyloid Imaging (HAI) Conference, the possibility of approval, potentially within months, of the first amyloid-scanning compound for clinical use hung over the room.
University Hospitals Case Medical Center is one of 12 sites conducting the first Phase 2 clinical trial of a gene therapy for Alzheimer's disease (AD). The study uses a viral-based gene transfer system called CERE-110, which is designed to deliver nerve growth factor (NGF) into the brain.
Epilepsy remains one of the most common neurological conditions, affecting one in 26 Americans in their lifetime, with one-third having a form of the condition that resists treatment or effective management. With those statistics in mind, more than 5,200 neurologists, scientists, nurses and health professionals came to Philadelphia December 4-8 for the 2015 American Epilepsy Society Annual Meeting to discuss new discoveries and emerging technologies that can lead to more effective treatment.
Cardium Therapeutics announced that it has gained exclusive access to commercial development rights for certain novel supramacromolecular polymer complexes enabling regulatable and localized topical delivery of nitric oxide for prolonged periods of one to three weeks, to broaden and expand the Company's wound healing and tissue regeneration portfolio.
› Verified 8 days ago
Carmen Gisela Romero-ortiz, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 193-15 Calle 526, Carolina, PR 00985 Phone: 254-681-9564 | |
Lilliana Villar Menendez, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: Km 8. P.r 3, Calle 3, Carolina, PR 00984 Phone: 787-757-1800 | |
Giovanni Antonio Mictil, MSN - CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 66-4 Calle 53, Carolina, PR 00985 Phone: 787-233-5986 |